None listed
Conditions
Interventions
Dietary Supplement : - experimantal group(Cordyceps militaris Extract, 60 people)
- placebo group(60 people)
* usage and capacity
- intake 1 pack/time and 1 time a day (1 pack/day)
- intake for 12 we
Sponsors
Chonbuk National University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) 40 years old - 60 years old woman who has passed one year or more since last menstrual period 2) Women with a Kupperman Index score of 20 or higher 3) Women who dicided to voluntarily participate in this clinical trial and complete to sign on the informed consent
Exclusion criteria
Exclusion criteria: 1) A person with a body mass index (BMI) exceeding 30 kg / m2 2) Woman who have used hormone preparations such as female hormones within the last 3 months 3) Those who have past or present history of endocervical hyperplasia, uterine cancer, breast cancer or mastopathy and cancer related to sex hormones. 4) Those who have had severe migraine within the last year, have been diagnosed with thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or have a history of performing transluminal coronary angioplasty. 5) People who have severe mental illness, such as depression and anxiety disorder, or are currently taking psychosomatic drugs such as antidepressants. 6) A person with metrorrhagia after one year of menopause. 7) Unregulated hypertension patinet (above 160/100 mmHg, measurement standard after 10 minutes of stabilization) 8) A diabetic whose blood glucose is not regulated (In case a new drug is started due to diabetes within three months or more than 180 mg/dL per fasting blood glucose). 9) A person with an unregulated thyroid disease (Anyone who is deemed able to participate in this human application test by the tester can participate). 10) A person who abuse drug or alcohol 11) Those whose ALT or AST exceeds three times the normal upper limit of the test organization 12) Those whose creatine exceeds the normal upper limit of the test organization 13) Anyone under the normal range test organization is FSH 14) Those who have clinically significant abnormalities in the Mammography/PAP smear 15) Those who have used clonidine, anticoagulant or anticoagulant within the last three months. 16) Those who have taken drugs or funtional foods related to women's adolescence within the last month. 17) Those who are taking or administering a treatment for osteoporosis, such as bisphosphonate. 18) Woman who involved in other clinical trial within 2 months before screening test or or plan to participate other clinical trial during the trial period 19) Woman who deemed inappropriate to participate this clinical trial by research director
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total sores of kupperman index(KMI, 11 items) | — |
Secondary
| Measure | Time frame |
|---|---|
| Estradiol (E2) and Follicle stimulating hormone (FSH) in blood;Thickness of endometrium;Laboratory test;Individual items of modified KIM (11 items and vaginal dryness item);Menopause rating scale (MRS);Alkaline phosphatase (ALP) and osteocalcin (OC) in blood | — |
Countries
Korea, Republic of
Contacts
Public ContactWoo-Rim Kim
Chonbuk National University Hospital
Outcome results
None listed